Meitheal Pharmaceuticals joins Biosimilars Forum
Meitheal, a fully integrated generic injectables company based in Chicago, has joined the Biosimilars Forum, a growing coalition of companies that work together to make safe, effective and lower-cost biosimilars accessible to the patients that need them.
“As a fully integrated biopharmaceutical company, Meitheal is thrilled to join the Biosimilars Forum,” said Tom Shea, CEO of Meitheal. “The creation of a sustainable and competitive marketplace for biosimilars has the potential to improve patient access, increase treatment options and generate savings and efficiencies.”
Biosimilars have the potential to save billions of dollars in U.S. healthcare spending—but this potential can only be fully harnessed if they are included on formularies. The Biosimilars Forum, a coalition of companies with the most significant biosimilars development portfolios in the U.S. and globally, is actively working to advance biosimilars in the U.S., with the ultimate goals of broadening access, enhancing availability and improving healthcare outcomes.
[Read more: AAM report: Generic, biosimilar drugs generate $408B in savings]
“The Forum’s Board of Directors and I are delighted that Meitheal is joining our organization at the most critical juncture in the U.S. biosimilar industry’s history,” said Juliana Reed, executive director of the Biosimilars Forum. “The Biosimilars Forum is committed to fostering a competitive marketplace that enables safe, effective and lower-cost biosimilars to thrive.”
In September, through its parent company, Hong Kong King-Friend Industry, Meitheal followed through on that purpose with an exclusive licensing agreement to commercialize three insulin biosimilars—insulin aspart, insulin lispro and insulin glargine—in the United States to increase treatment options and solve challenges for people living with diabetes.
“We look forward to working together with the Biosimilars Forum to create significant savings for the U.S. healthcare system and increase access to life-saving treatments,” said Shea.
[Read more: Challenges continue, but generics companies see a bright future with biosimilars]